Analysts Viewpoint 0 analysts rank CRDF stock as an Overweight The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
Analysts Viewpoint A Guide To The Risks Of Investing In Cardiff Oncology Inc (CRDF) Cardiff Oncology Inc’s filing revealed that its Director PACE GARY W acquired Company’s shares for reported $0.67 million on Jul
Analysts Viewpoint 0 analysts rank CRDF stock as an Overweight The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or